Home>>Uroguanylin Topoisomer A (human)

Uroguanylin Topoisomer A (human)

Catalog No.GA23661

Uroguanylin belongs to the guanylin family of cyclic guanosine monophosphate (cGMP) regulating peptides. This family of peptides shows homology to the heat stable enterotoxins produced by strains of Escherichia coli and other enteric bacteria that cause a secretory form of diarrhea. Along with the isolation of uroguanylin from urine and the subsequent demonstration of its natriuretic activity by direct effects on the kidney, uroguanylin has been suggested to play a role in the physiological maintenance of sodium balance in vivo. Uroguanylin activation of the guanylate cyclase-C/cyclic guanosine monophosphate pathway elicited analgesic effects in animal models of colonic hypersensitivity, unraveling a novel pathway to treat abdominal pain (Silos-Santiago et al. (2013)).

Products are for research use only. Not for human use. We do not sell to patients.

Uroguanylin Topoisomer A (human) Chemical Structure

Cas No.: 154525-25-4

Size Price Stock Qty
0.5mg
$602.00
In stock
1mg
$1,073.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Uroguanylin belongs to the guanylin family of cyclic guanosine monophosphate (cGMP) regulating peptides. This family of peptides shows homology to the heat stable enterotoxins produced by strains of Escherichia coli and other enteric bacteria that caus

Reviews

Review for Uroguanylin Topoisomer A (human)

Average Rating: 5 ★★★★★ (Based on Reviews and 28 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Uroguanylin Topoisomer A (human)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.